Skip to main content
. 2012 Mar 27;109(15):5797–5802. doi: 10.1073/pnas.1117208109

Table 1.

Summary of Ab, CD4, and CD8 responses in ovarian cancer and melanoma patients

Ovarian (n = 22) Melanoma (n = 25)
Antibody responses
 Baseline seropositives 3 10
 Baseline seronegatives 19 15
 Seroconversions 8/19 (42%) 5/15 (33%)
 Total posttreatment seropositives 11/22 (50%) 15/25 (60%)
CD4+ T-cell responses
 Preexisting 15/22 (68%) 12/23 (52%)
 Postvaccination 20/22 (91%) 18/23 (78%)
CD8+ T-cell responses
 Preexisting 3/22 (14%) 10/25 (40%)
 Postvaccination 10/22 (45%) 22/25 (88%)